Industry
Biotechnology
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Loading...
Open
22.44
Mkt cap
349M
Volume
250K
High
24.35
P/E Ratio
-5.97
52-wk high
74.49
Low
21.86
Div yield
N/A
52-wk low
12.49
Portfolio Pulse from
December 17, 2024 | 4:45 pm
Portfolio Pulse from
December 16, 2024 | 7:30 pm
Portfolio Pulse from
December 15, 2024 | 5:15 pm
Portfolio Pulse from
December 13, 2024 | 5:15 pm
Portfolio Pulse from
December 11, 2024 | 7:45 pm
Portfolio Pulse from
December 04, 2024 | 12:30 am
Portfolio Pulse from
November 28, 2024 | 3:15 pm
Portfolio Pulse from
November 27, 2024 | 5:15 pm
Portfolio Pulse from
November 27, 2024 | 3:15 pm
Portfolio Pulse from
November 26, 2024 | 9:15 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.